Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-group Treatment, Phase 3, Double-blind, Randomized, 2-arm Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735 is registered in ClinicalTrials.gov with VectivBio AG as lead sponsor.

NCT NCT07742735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07742735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-group Treatment, Phase 3, Double-blind, Randomized, 2-arm Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
Lead sponsor
VectivBio AG
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
October 31, 2029
Enrollment
124 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

sbs associated with intestinal failure (sbs-if), short bowel syndrome (sbs)